The present invention is directed to a hemostatic semi-solid paste material comprising a bioabsorbable carrier hemostatic material; and a supplemental hemostatic agent; wherein the paste material has an elongated form extending along a lengthwise axis with an aspect ratio of at least 3; wherein the paste is self-supporting and syringe extrudable; and wherein the supplemental hemostatic agent has a non-homogenous distribution profile across a cross-section taken across the lengthwise axis. In another aspect, the present invention relates to devices for forming and expressing the hemostatic material.

An enhanced medical dressing for treatment of wounds is provided. A dressing is augmented by one or more enhancers thereon. The enhancers include a collagen, an antibiotic, or both. The enhanced medical dressing is prepared by placing and mixing the collagen, the antibiotic, and the dressing within a container. On mixing, the enhanced medical dressing is formed such that the enhancer adheres to the dressing by, for example, adsorption or an electrostatic force. The enhanced medical dressing when applied to the wound causes the collagen and the antibiotic to be released into the wound. Further, the enhanced medical dressing degrades over time due to contact with physiological moisture.

Cells for increased collagen production are engineered by a novel CRISPR cellular engineering process. The process can be carried out using human cells or even patient-harvested cells. Collagen produced by the cells has a low risk of immunogenicity when implanted into human patients compared to collagen produced by non-human cells. Cell culture media including chemical additives are also provided to have a further positive effect on collagen production.

The method of making a hydrolyzed collagen gel is a manufacturing method for producing a hydrolyzed collagen gel to be used as a topical wound treatment. A first volume of purified water is initially heated to a temperature ranging from about 71 C. to about 77 C., and a hydrolyzed type I collagen powder is then mixed into the heated purified water to form a first mixture. An additive is mixed into the first mixture to form a second mixture, where the additive may be native collagen, at least one amino acid, least one therapeutic agent, gelatin, whey, hydrolyzed whey, polysulfated glycosaminoglycan, a glucosamine salt, glutamine, glycosaminoclycans, zinc, silver oxide alginates, cellulose, honey, mushroom extract and combinations thereof. A second volume of purified water is then added to the second mixture to form the hydrolyzed collagen gel product. Mixing is performed as a continuous, recirculating, temperature-monitored and temperature-maintained process.

A sheet material that can be used as a wound dressing and contains elemental metal particles.

This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.

Provided is a method for biosynthesis of a human body structural material type-VIII collagen. Also provided is a collagen, comprising one or more repeating units, wherein the repeating units are connected directly or by means of linkers, and each repeating unit comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a variant thereof. The collagen can be used for biological dressings, human body bionic materials or plastic surgery materials. According to the method, the type-VIII collagen is produced by utilizing a genetic engineering technology, thereby overcoming the defects in the prior art.

A method for processing placental tissue, including steps of: exposing a placenta tissue sample in a weak acid environment to obtain a first placenta tissue semi-finished product; performing a flushing procedure for the first placenta tissue semi-finished product to obtain a second placenta tissue semi-finished product, wherein the flushing procedure includes a first flushing procedure using a neutral buffer, a disinfection procedure using a mixture of the neutral buffer and at least one antibiotic, and a second flushing procedure using the neutral buffer to remove the at least one antibiotic; and making the second placenta tissue semi-finished product dehydrated or frozen in extremely low temperatures to obtain a final placenta tissue product.

This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.

The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glyclosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.